Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016', provides in depth analysis on Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted pipeline therapeutics. 

The report provides comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Overview 7
Therapeutics Development 8
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Stage of Development 8
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Therapy Area 9
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Indication 10
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Companies 13
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development 21
Alteogen Inc. 21
Clearside BioMedical, Inc. 22
CSL Limited 23
Eli Lilly and Company 24
Formycon AG 25
Regeneron Pharmaceuticals, Inc. 26
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles 27
(aflibercept + nesvacumab) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(aflibercept + rinucumab) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(aflibercept + triamcinolone acetonide) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
2H-10 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
aflibercept - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
aflibercept biosimilar - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
aflibercept biosimilar - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CSL-346 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ziv-aflibercept - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Projects 51
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products 52
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Featured News & Press Releases 53
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 53
May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 54
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 54
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 55
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 56
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 56
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 57
Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 57
Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema 58
Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition 59
Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan 59
Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance 60
May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice 60
Apr 01, 2015: New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection 62
Mar 25, 2015: EYLEA (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Alteogen Inc., H2 2016 21
Pipeline by Clearside BioMedical, Inc., H2 2016 22
Pipeline by CSL Limited, H2 2016 23
Pipeline by Eli Lilly and Company, H2 2016 24
Pipeline by Formycon AG, H2 2016 25
Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 26
Dormant Projects, H2 2016 51
Discontinued Products, H2 2016 52